Acid sphingomyelinase protein and methods of treating type B...

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S071100, C435S183000, C435S195000, C435S196000, C536S023500, C536S023700, C530S350000, C514S002600

Reexamination Certificate

active

06541218

ABSTRACT:

1. INTRODUCTION
The present invention relates to the acid sphingomyelinase gene and to methods of diagnosing Niemann-Pick disease. It is based, at least in part, on the cloning and expression of the full-length cDNA encoding acid sphingomyelinase, the cloning and characterization of the genomic structure of the acid sphingomyelinase gene, and on the discovery of a frequent missense mutation in the acid sphingomyelinase gene of Ashkenazi Jewish Niemann-Pick disease patients.
2. BACKGROUND OF THE INVENTION
Types A and B Niemann-Pick disease (NPD) are autosomal recessive disorders resulting from the deficient activity of the lysosomal hydrolase, acid sphingomyelinase (ASM; sphingomyelin cholinephosphohydrolase, E:C 3.1.3.12) and the accumulation of sphingomyelin, primarily in reticuloendothelial lysosomes (Niemann, 1914, Fahrb. Kinderheikd, 79:1-6; Brady et al., 1966, Proc. Natl. Acad. Sci. U.S.A. 55;366-369; Fredrickson, 1966, in “The Metabolic Basis of Inherited Disease; Stanbury et al., eds., 2nd Ed., McGraw-Hill, New York, pp. 586-602; Spence and Callahan, 1989, in “The Metabolic Basis of Inherited Disease,” Scriver et al., eds., 8th Ed., McGraw-Hill, New York, pp. 1655-1676). Type A disease is a rapidly progressive neurodegenerative disease of infancy manifested by failure to thrive, severe psychomotor retardation, hepatosplenomegaly, and demise by 2-3 years of age. In comparison, type B disease is characterized primarily by reticuloendothelial system sphingomyelin deposition leading to hepatosplenomegaly and pulmonary involvement, the absence of neurologic manifestations, and survival into adulthood. The nature of the biochemical and molecular defects that underlie the remarkable clinical heterogeneity of the A and B subtypes remains unknown. Although patients with both subtypes have residual ASM activity (about 1 to 10% of normal), biochemical analysis cannot reliably distinguish the two phenotypes. Moreover, the clinical course of Type B NPD is highly variable, and it is not presently possible to correlate disease severity with the level of residual ASM activity.
Types A and B NPD occur at least 10 times more frequently among individuals of Ashkenazi Jewish ancestry than in the general population. It is estimated that the incidence of the type A disease among Ashkenazi Jews is about 1 in 40,000, a gene frequency (q) of about 1 in 200, and a heterozygote frequency (2 pq) of 1 in 100 (Goodman, 1979, in “Genetic Disorders Among The Jewish People”, John Hopkins Univ. Press, Baltimore, pp. 96-100). The incidence of type B NPD in the Ashkenazi Jewish population is less frequent, perhaps 1 in 80 (Goodman, supra). Thus, the combined heterozygotic frequency for types A and B NPD has been estimated to be about 1 in 70 among individuals of Ashkenazi Jewish decent. Although the enzymatic diagnosis of affected patients with either type A or B NPD can be made reliably (Spence and Callahan, supra), the enzymatic detection of obligate heterozygotes has proven problematic, particularly using peripheral leukocytes as the enzyme source. Presumably, the occurrence of neutral sphingomyelinases in some sources and/or the presence of residual ASM activity resulting from the mutant allele have contributed to the inability to reliably discriminate carriers for either disease subtype. Even the use of cultured skin fibroblasts, which do not express the neutral sphingomyelinase, has not provided unambiguous results with obligate heterozygotes.
Recently, two partial cDNAs encoding human ASM were isolated and sequenced (Quintern et al., 1989, EMBO J. 8:2469-2473). The type 1 cDNA contained an in-frame 172 base pairs (bp) encoding 57 amino acids; in the type 2 cDNA this sequence was replaced by an in-frame 40 bp encoding 13 different amino acids. Of the 92 positive clones identified by cDNA library screening, the type 1 and 2 cDNAs represented about 90% and 10%, respectively (Quintern et al., supra).
3. SUMMARY OF THE INVENTION
The present invention relates to the ASM gene and to methods of diagnosing Niemann-Pick disease (NPD). It is based, at least in part, on the cloning and characterization of full-length cDNAs corresponding to three ASM gene transcripts and the recognition that one species of transcript could be expressed to form the active ASM enzyme. The present invention is further based on the discovery of a frequent missense mutation in the ASM gene that was detected in 32 percent of the Ashkenazi Jewish NPD type A alleles but in only 5.6 percent of ASM alleles from non-Jewish type A patients, and the discovery of a deletion mutant of the ASM gene that is associated with NPD type B disease. Additionally, the genomic sequence and structure of the ASM gene is elucidated herein.
The present invention provides for nucleic acid encoding ASM, substantially purified ASM protein and fragments and derivatives thereof, expression systems for producing ASM, genetically engineered cells and organisms containing a recombinant full-length ASM gene, probes that may be used to diagnose mutations in ASM, assay systems for the diagnosis of NPD, and methods of treatment of NPD.
In one preferred embodiment of the invention, such an assay system may be used to determine the presence of a mutation that results in an arginine to leucine substitution at amino acid residue 496 in Ashkenazi Jewish NPD patients and in prenatal diagnosis, said mutation being associated with NPD type A.
In another preferred embodiment of the invention, such an assay system may be used to determine the presence of a mutation that results in a deletion of an arginine residue at amino acid position 608 in Ashkenazi Jewish NPD patients and in prenatal diagnosis, said mutation being associated with NPD type B.


REFERENCES:
patent: 5773278 (1998-06-01), Schuchman et al.
patent: 0 161 788 (1985-11-01), None
Levran et al PNAS 88: 3748-3752 (May 1991).*
Quintern et al. EMBO J. 8(9): 2469-2473 (1989).*
Schuchman et al. AM J. Hum. Genet 45: A217 (1989).*
Miranda, et al. FASEB Journal (Oct. 2000) 14(13): 1988-1995.*
Barton and Neufeld, 1971, “The Hurler corrective factor. Purification and some properties”, J. Biol. Chem. 246:7773-7779.
Beutler et al., 1977, “Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation”, Proc. Natl. Acad. Sci. USA 74:4620-4623.
Fischer et al., 1980, “Phosphomannosyl-enzyme receptors in rat liver”, J. Biol. Chem. 255:9608-9615.
Furbish et al., 1977, “Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocerebrosidase suitable for human administration”, Proc. Natl. Acad. Sci. USA 74:3560-3563.
Koch et al., 1996, “Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase”, J. Biol. Chem. 271:33110-33115.
Krivit et al., 1973, “Prospectus”, Birth Defects: Original Article Series IX:232-233.
Levran et al., 1992, “Identification and expression of a common missense mutatin (L302P) in the acid sphingomyelinase gene of Ashkenazi Jewish type A Niemann-Pick disease patients”, Blood 80:2081-2087.
Pentchev, 1977, “Enzyme replacement therapy in Gaucher's and Fabry's disease”, Ann. Clin. Lab. Sci. 7:251-253.
Takahashi et al., 1992, “Identification and expression of five mutations in the human acid sphingomyelinase gene causing types A and B Niemann-Pick disease. Molecular evidence for genetic heterogeneity in the neuropathic and non-neuropathic forms”, J. Biol. Chem. 267:12552-12558.
van der Ploeg et al., 1988, “Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells”, J. Neurol. 235:392-396.
van der Ploeg et al., 1987, “Breakdown of lysosomal glycogen in cultured fibroblasts from glycogenosis type II patients after uptake of acid &agr;-glucosidase”, J. Neurological Sci. 79:327-336.
Merril et al., 1979, “Trace polypeptides in cellular extracts and human body fluids detected by two-dimensional electrophoresis and highly sensitive silver stain”, Proc. Natl. Acad. Sci. USA 76:4335-4339.
Switzer et al., 1979, “A highly sensitive silver strain for detecting proteins

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Acid sphingomyelinase protein and methods of treating type B... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Acid sphingomyelinase protein and methods of treating type B..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acid sphingomyelinase protein and methods of treating type B... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3054695

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.